Test Code LAB9050 Quad Screen (Second Trimester) Maternal, Serum
Additional Codes
LAB9050 QUAD1
Necessary Information
In order to provide the best results, either answer the order entry questions or provide the required information using the Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595).
Specimen Required
Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Do not collect specimen after amniocentesis as this could affect results.
2. Centrifuge and aliquot serum into plastic vial within 2 hours of collection
Additional Information:
1. For an assessment that includes neural tube defect results, gestational age must be between 15 weeks, 0 days and 22 weeks, 6 days.
2. Assessments for trisomy 21 (Down syndrome) and trisomy 18 (Edwards syndrome) only are available between 14 weeks, 0 days and 22 weeks, 6 days.
3. Initial or repeat testing is determined in the laboratory at the time of report and will be reported accordingly. To be considered a repeat test for the patient, the testing must be within the same pregnancy and trimester, with interpretable results for the same tests, and both tests are performed at Mayo Clinic.
4. Maternal Serum Screening patient education brochure (T522) is available upon request.
Forms
Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595) is required.
Secondary ID
113145Useful For
Prenatal screening for open neural tube defect (alpha-fetoprotein only), trisomy 21 (alpha-fetoprotein, human chorionic gonadotropin, estriol, and inhibin A) and trisomy 18 (alpha-fetoprotein, human chorionic gonadotropin, and estriol)
Special Instructions
Method Name
Immunoenzymatic Assay
Specimen Type
SerumSpecimen Minimum Volume
0.75 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 7 days | |
Frozen | 90 days | ||
Ambient | 7 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | OK |
Gross icterus | OK |
Reference Values
NEURAL TUBE DEFECTS:
An alpha-fetoprotein (AFP) multiple of the median (MoM) <2.5 is reported as screen negative.
AFP MoM ≥2.5 (singleton and twin pregnancies) are reported as screen positive.
DOWN SYNDROME:
Calculated screen risks <1/270 are reported as screen negative, risks ≥1/270 are reported as screen positive.
TRISOMY 18:
Calculated screen risks <1/100 are reported as screen negative, risks ≥1/100 are reported as screen positive.
An interpretive report will be provided.
Interpretation
Neural Tube Defects
A screen-negative result indicates that the calculated alpha-fetoprotein (AFP) multiple of the median (MoM) falls below the established cutoff of 2.50 MoM. A negative screen does not guarantee the absence of neural tube defects (NTD).
A screen-positive result indicates that the calculated AFP MoM is 2.50 or greater and may indicate an increased risk for open NTD. The actual risk depends on the level of AFP and the individual's pretest risk of having a child with NTD based on family history, geographical location, maternal conditions such as diabetes and epilepsy, and use of folate prior to conception. A screen-positive result does not infer a definitive diagnosis of NTD but indicates that further evaluation should be considered. Approximately 80% of pregnancies affected with NTD have elevated AFP, MoM values greater than 2.5.
Trisomy 21 (Down syndrome) and Trisomy 18 (Edwards syndrome):
A screen-negative result indicates that the calculated screen risk is below the established cutoff of 1/270 for trisomy 21 and 1/100 for trisomy 18. A negative screen does not guarantee the absence of trisomy 21 or trisomy 18.
When a trisomy 21 second-trimester risk cutoff of 1/270 is used for follow-up, the combination of maternal age, AFP, estriol, human chorionic gonadotropin, and inhibin A has an overall detection rate of approximately 77% to 81% with a false-positive rate of 6% to 7%. In practice, both the detection rate and false-positive rate increase with age. The detection rate ranges from 66% (early teens) to 99% (late 40s), with false-positive rates of between 3% and 62%, respectively.
The detection rate for trisomy 18 is 60% to 80% using a second trimester cutoff of 1/100.
Follow-up
Upon receiving maternal serum screening results, all information used in the risk calculation should be reviewed for accuracy (maternal date of birth, gestational dating, etc). If any information is incorrect, the laboratory should be contacted for a recalculation of the estimated risks.
Screen-negative results typically do not warrant further evaluation.
Ultrasound is recommended to confirm dates for NTD or trisomy 21 screen-positive results. Many pregnancies affected with trisomy 18 are small for gestational age. Recalculations that lower the gestational age may decrease the detection rate for trisomy 18. If ultrasound yields new dates that differ by at least 7 days, a recalculation should be considered. If dates are confirmed, high-resolution ultrasound and amniocentesis (including amniotic fluid AFP and acetylcholinesterase measurements for NTD) are typically offered.
Method Description
This 4-marker screen includes alpha-fetoprotein (AFP), estriol (uE3), human chorionic gonadotropin (total beta-hCG: ThCG), and inhibin A. Analyte values are compared to median values at a given gestational age and multiple of the median (MoM) results obtained. The MoM results are used in a multivariate algorithm that includes the mother's age to derive risk factors for trisomy 21 (Down syndrome) and trisomy 18 (Edwards syndrome). The screen for neural tube defects (NTD) uses the AFP MoM only. An interpretive report will be provided. The Beckman Access AFP, ThCG, uE3, and inhibin A assays are automated immunoenzymatic assays with paramagnetic separation and chemiluminescent detection.(Package insert: Beckman Coulter Access AFP, Total bhCG, Unconjugated Estriol, and Inhibin A. Beckman Coulter; 2019)
Day(s) Performed
Monday through Friday
Report Available
4 to 6 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
81511
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
QUAD1 | QUAD SCRN (2nd Tri) Maternal, S | 48800-7 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
7058 | Recalculated Maternal Serum Screen | 32399-8 |
113146 | Results Summary | 32399-8 |
10334 | Down syndrome screen risk estimate | 43995-0 |
10335 | Down syndrome maternal age risk | 49090-4 |
10337 | Trisomy 18 screen risk estimate | 43994-3 |
113147 | Neural tube defect risk estimate | 48803-1 |
10351 | AFP | 83073-7 |
113148 | AFP MoM | 23811-3 |
601921 | AFP MoM (14,0-14,6) | 23811-3 |
10352 | uE3 | 2250-9 |
113149 | uE3 MoM | 21264-7 |
10353 | hCG, TOTAL | 83086-9 |
113150 | hCG, TOTAL MoM | 23841-0 |
113151 | INHIBIN MoM | 36904-1 |
10354 | INHIBIN | 2478-6 |
10356 | INTERPRETATION | 49092-0 |
10357 | RECOMMENDED FOLLOW UP | 80615-8 |
10248 | Additional comments | 48767-8 |
3009 | Specimen collection date | 33882-2 |
7823 | Maternal date of birth | 21112-8 |
7834 | Calculated age at EDD | 43993-5 |
26717 | Maternal Weight | 29463-7 |
26718 | Maternal Weight | 29463-7 |
IDD | Insulin dependent diabetes | 44877-9 |
RACE1 | Patient race | 21484-1 |
SMKNG | Current cigarette smoking status | 64234-8 |
10054 | EDD by U/S scan | 11781-2 |
7203 | GA on collection by U/S scan | 11888-5 |
7753 | EDD by LMP | 11779-6 |
7204 | GA on collection by dates | 11885-1 |
7830 | GA used in risk estimate | 21299-3 |
MULTF | Number of Fetuses | 55281-0 |
CHOR_ | Number of Chorions | 92568-5 |
IVFP | IVF pregnancy | 47224-1 |
PRHIS | Prev Down (T21) / Trisomy Pregnancy | 53826-4 |
PRNTD | Prev Pregnancy w/ Neural Tube Defect | 53827-2 |
PTNTD | Patient or father of baby has a NTD | 53827-2 |
INTL | Initial or repeat testing | 77202-0 |
DRPHN | Physician Phone Number | 68340-9 |
10358 | GENERAL TEST INFORMATION | 62364-5 |